InventisBio Co., Limited (SHA:688382)

China flag China · Delayed Price · Currency is CNY
23.60
-0.12 (-0.51%)
At close: May 23, 2025, 2:57 PM CST
170.95%
Market Cap 18.37B
Revenue (ttm) 168.37M
Net Income (ttm) -214.53M
Shares Out 578.33M
EPS (ttm) -0.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,503,871
Average Volume 10,877,681
Open 23.61
Previous Close 23.72
Day's Range 23.41 - 24.40
52-Week Range 6.50 - 24.42
Beta 0.29
RSI 80.35
Earnings Date Aug 27, 2025

About InventisBio

InventisBio Co., Limited, a clinical stage biotech company, engages in the discovery and development of therapeutics for cancer and metabolic diseases in China and the United States. The company’s drug candidates for the oncology therapeutic area include BPI-D0316, which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; D-0502, which is in Phase I clinical trial for the breast cancer indications; and D-1553, which in Phase I clinical trial for NSCLS, colorectal cancer indications. Its drug candidates for the... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 185
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688382
Full Company Profile

Financial Performance

In 2024, InventisBio's revenue was 168.79 million, a decrease of -9.02% compared to the previous year's 185.53 million. Losses were -240.20 million, -15.41% less than in 2023.

Financial Statements

News

There is no news available yet.